Tafamidis meglumine
Based on 2 publication(s) in Google Scholar
Tafamidis meglumine (Fx-1006A) is an orally active and selective transthyretin (TTR) stabilizer. Tafamidis meglumine binds to the thyroxine binding site with negative cooperativity, stabilizes the TTR tetramer, slows TTR tetramer dissociation and subunit exchange, and inhibits TTR fibril formation. Tafamidis meglumine can be used in research on nervous system-related diseases.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit : 99.95%
- CAS. Nr.: 951395-08-7
- Formel: C21H24Cl2N2O8
- Molecular Weight:503.33
-
Speicherung:
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
-
Lösungsmittel & Löslichkeit
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
-
HY-14852
TafamidisTTR Stabilizer -
HY-13803
TazemetostatEZH2 Inhibitor -
HY-16985
DarolutamideAndrogen Receptor Antagonist -
HY-B0083
LeflunomideDHODH Inhibitor -
HY-14852AR
Tafamidis meglumine (Standard)Reference Standard -
HY-14852R
Tafamidis (Standard)Reference Standard -
HY-107633
A 1120RBP4 Antagonist -
HY-109165
AcoramidisTransthyretin Stabilizer -
HY-109165A
Acoramidis hydrochlorideTransthyretin Stabilizer -
HY-113950
Dichlorophenyl-ABATTR Amyloid Fibril Formation Inhibitor -
HY-153577
WT-TTR inhibitor 1WT-TTR Inhibitor -
HY-107633R
A 1120 (Standard)Reference Standard
Publications Citing Use of MedChemExpress (MCE) Tafamidis meglumine
More
Biologische Aktivität
Beschreibung
In Vitro
Tafamidis meglumine is highly bound to rat plasma proteins, with a binding rate of 99.8% at 2 μg/mL and a blood-to-plasma partition ratio of 56.6%[1].
Tafamidis meglumine binds recombinant wild-type TTR and human plasma TTR with high selectivity and high affinity, and effectively inhibits the dissociation of wild-type TTR and more than 35 TTR mutant heterotetramers, including Val30Met and Val122Ile; it stabilizes TTR tetramers by slowing subunit exchange of the TTR tetramer and inhibiting tetramer dissociation[2].
Tafamidis meglumine inhibits WT, V30M, and V122I TTR fibril formation with an EC50 of 2.7-3.2 μM[3].
Tafamidis meglumine shows a dose-dependent kinetic stabilization effect on WT-TTR under 6.5 M urea conditions, reducing dissociation to 33% at a 1:1 molar ratio and to below 3% at 2:1[3].
Tafamidis meglumine binds WT-TTR with negative cooperativity, yielding Kd1 = 2 nM and Kd2 = 154 nM as derived from subunit exchange modeling[3].
Tafamidis meglumine binding to TTR exhibits negative cooperativity, and the dissociation constants of its two binding sites are determined by two methods: single-exponential fitting of binding and second-order binding polynomial fitting yield Kd1 = 2 nM and Kd2 = 154 nM; isothermal titration calorimetry measurements yield Kd1 = 3 nM and Kd2 = 278 nM[3].
Tafamidis meglumine selectively binds TTR in human plasma; in human plasma systems, it resists 4.8 M urea denaturation and exerts a stabilizing effect on wild-type, V30M, and V122I TTR tetramers; moreover, in a urea-denaturing environment, it also stabilizes various TTR variants in human plasma, including V30M, Y69H, F64S, I84S, V122I, and L111M[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS. Nr. 951395-08-7
-
Appearance Solid
-
Molecular Weight 503.33
-
Formel C21H24Cl2N2O8
-
Color White to off-white
-
SMILES
O=C(C1=CC=C2N=C(C3=CC(Cl)=CC(Cl)=C3)OC2=C1)O.O[C@@H]([C@@H]([C@@H](CO)O)O)[C@@H](O)CNC
-
Synonyms
Fx-1006A
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Publications (2)
-
Journal Impact Factor
-
Most Recent
-
J Med Chem
Repositioning of the Anthelmintic Drugs Bithionol and Triclabendazole as Transthyretin Amyloidogenesis Inhibitors. [Abstract]2021 Oct 14;64(19):14344-14357. PMID: 34547896 -
Vascul Pharmacol
Antithrombotic properties of Tafamidis: An additional protective effect for transthyretin amyloid cardiomyopathy patients. [Abstract]2024 Jul 17:107411. PMID: 39029855
Lösungsmittel & Löslichkeit
In Vitro:
DMSO : 12.5 mg/mL (24.83 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
H2O : < 0.1 mg/mL (insoluble)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 1.25 mg/mL (2.48 mM); Clear solution
This protocol yields a clear solution of ≥ 1.25 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (12.5 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 1.25 mg/mL (2.48 mM); Clear solution
This protocol yields a clear solution of ≥ 1.25 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (12.5 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Reinheit & Dokumentation
-
Data Sheet (298 KB)
-
SDS (644 KB)
- English - EN (644 KB)
- Français - FR (644 KB)
- Deutsch - DE (644 KB)
- Norwegian - NO (644 KB)
- Español - ES (644 KB)
- Swedish - SV (644 KB)
- Italian - IT (644 KB)
- Korean - KR (644 KB)
- Portuguese - PT (644 KB)
-
Handling Instructions (2659 KB)
Verweise
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.9868 mL | 9.9338 mL | 19.8677 mL | 49.6692 mL |
| 5 mM | 0.3974 mL | 1.9868 mL | 3.9735 mL | 9.9338 mL | |
| 10 mM | 0.1987 mL | 0.9934 mL | 1.9868 mL | 4.9669 mL | |
| 15 mM | 0.1325 mL | 0.6623 mL | 1.3245 mL | 3.3113 mL | |
| 20 mM | 0.0993 mL | 0.4967 mL | 0.9934 mL | 2.4835 mL |
Tafamidis meglumine Related Classifications
HY-14852A Related Classifications
Powered by Bioz